Breast Cancer Clinical Trial
— iWEBOfficial title:
An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program
Verified date | May 2015 |
Source | University of Vermont |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to test the effectiveness of a behavioral weight loss and
exercise intervention delivered via the internet at different cancer centers in New England.
The investigators hypothesize that participants will lose 7% of their body weight. The
research is being done because many women who are treated for breast cancer are overweight
and treatment for breast cancer is often accompanied by weight gain. Individuals who are
overweight may be more likely to have their breast cancer come back. Also women who exercise
at least three hours a week seem to have less chance of their cancer coming back. The
investigators hope to identify an effective weight loss and exercise intervention for breast
cancer survivors that can be easily accessed by many people.
This study is designed to determine the feasibility of conducting a distantly
delivered-weight loss and exercise intervention for patients who have been treated for
breast cancer at three cancer centers, and to evaluate the efficacy of an Internet-based
behavioral weight loss and exercise intervention delivered to overweight/obese breast cancer
survivors in three New England locations.
Participants will be recruited from three New England Cancer Centers - the Vermont Cancer
Center, Norris Cotton Cancer Center at Dartmouth University and the University of
Massachusetts Cancer Center. Participants from each center will undergo baseline assessments
that include diet assessment, body measurements (height, weight, etc), a physical activity
assessment and be asked to complete a series of questionnaires.
Patients that meet the minimum requirements will be enrolled on the study. They will
participate in weekly on-line "chats" about behavioral and diet modifications led by a
qualified facilitator. Participants will also engage in increasing amounts of aerobic
activity (typically walking) throughout the course of the intervention. The intervention
lasts 6 months. At the end of those 6 months, participants will have the same assessments
that were collected at baseline. Following the collection of those assessments, participants
will have completed the study.
Status | Active, not recruiting |
Enrollment | 48 |
Est. completion date | July 2015 |
Est. primary completion date | July 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 21 Years to 69 Years |
Eligibility |
Inclusion Criteria: - breast cancer diagnosis - Completion of surgery, chemotherapy +/- radiation for stage I, II, or III breast cancer 2-12 months prior to study initiation - BMI between 27 and 50 - patient self-report of ability to walk for 10 minutes without interruption or pain - access to computer and the internet Exclusion Criteria: - metastatic disease - prior receipt of chemotherapy for other malignancy - pregnancy at the time of study entry - limited food choices due to celiac sprue or inflammatory bowel disease - illiteracy - non-English speaking |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Unviersity of Vermont/Fletcher Allen Health Care | Burlington | Vermont |
United States | Dartmouth Hitchcock Medical Center | Hannover | New Hampshire |
United States | University of Massachusetts | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
University of Vermont | Dartmouth-Hitchcock Medical Center, University of Massachusetts, Worcester |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility | Feasibility will be determined by length of time required to obtain approval at all three sites, Numbers approached vs. numbers who participate in the study. | Change from baseline fesability at 6 months | No |
Primary | Change in diet measures | Efficacy will be measured using total calories and fat grams before and after the intervention | Change from baseline diet measures at 6 months | No |
Primary | Change in anthropometric measures | Change in Weight, BMI, body fat percentage before and after the intervention | Change from baseline anthropometrics at 6 months | No |
Primary | Change in active energy expenditure (ie exercise) | exercise will be measured using an accelerometer before and after the intervention | Change from baseline active energy expenditure at 6 months | No |
Secondary | Change in inflammatory biomarkers | Change in Il-6, hsCRP before and after the intervention | Change from baseline inflammatory biomarkers at 6 months | No |
Secondary | Change in insulin resistance markers | Change in Homeostatic model assessment to estimate beta cell function and insulin resistance before and after the intervention | Change from baseline insulin resistance markers at 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |